非那雄胺局部治疗男性和女性雄激素性脱发的系统评价
A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women.
作者信息
Lee Sung Won, Juhasz Margit, Mobasher Pezhman, Ekelem Chloe, Mesinkovska Natasha Atanaskova
出版信息
J Drugs Dermatol. 2018 Apr 1;17(4):457-463.
INTRODUCTION
Currently, only topical minoxidil (MNX) and oral finasteride (FNS) are approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of androgenetic alopecia. Although FNS is efficacious for hair regrowth, its systemic use is associated with side effects limiting long-term utilization. Exploring topical FNS as an alternative treatment regimen may prove promising.
METHODS
A search was conducted to identify studies regarding human in vivo topical FNS treatment efficacy including clinically relevant case reports, randomized controlled trials (RCTs), and prospective studies.
RESULTS
Seven articles were included in this systematic review. In all studies, there was significant decrease in the rate of hair loss, increase in total and terminal hair counts, and positive hair growth assessment with topical FNS. Both scalp and plasma DHT significantly decreased with application of topical FNS; no changes in serum testosterone were noted.
CONCLUSION
Preliminary results on the use of topical FNS are limited, but safe and promising. Continued research into drug-delivery, ideal topical concentration and application frequency, side effects, and use for other alopecias will help to elucidate the full extent of topical FNS' use.
J Drugs Dermatol. 2018;17(4):457-463.
.引言
目前，只有外用米诺地尔（MNX）和口服非那雄胺（FNS）被美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）批准用于治疗雄激素性脱发。尽管非那雄胺对促进头发生长有效，但其全身用药会带来副作用，限制了长期使用。探索外用非那雄胺作为一种替代治疗方案可能很有前景。
方法
进行了一项检索，以确定关于人体外用非那雄胺治疗效果的研究，包括临床相关的病例报告、随机对照试验（RCT）和前瞻性研究。
结果
本系统评价纳入了7篇文章。在所有研究中，外用非那雄胺均使脱发率显著降低，总毛发数量和终毛数量增加，且对头发生长的评估呈阳性。外用非那雄胺后，头皮和血浆中的双氢睾酮（DHT）均显著降低；血清睾酮未见变化。
结论
外用非那雄胺的初步研究结果有限，但安全且有前景。对药物递送、理想的外用浓度和应用频率、副作用以及在其他脱发类型中的应用继续进行研究，将有助于阐明外用非那雄胺的全部应用范围。
《药物皮肤病学杂志》。2018年；17(4):457 - 463。
Zotero 插件